Compare Inovio Pharmaceuticals Inc (INO) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.48 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 643.6× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Vanguard Intermediate Term Corporate Bond ETF for 61 Days on average.
| INO | VCIT | |
|---|---|---|
Market Cap | $112.19M | $72.20B |
Volume | 3,201,278 | 7,532,796 |
Sector | Health | Fixed Income |
52-Week High | $2.65 | $84.82 |
52-Week Low | $0.66 | $77.98 |
Typical Hold Time | 43 Days | 61 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.155, up 2.21% today, while showing bearish technical signals with negative cash flow and substantial losses. The company's financials reveal minimal revenue of $65,340 against an $84.95 million net loss in 2025, with profitability metrics deeply negative. However, analyst sentiment is optimistic with a 58.83% buy rating and $2.75 consensus price target, driven by the upcoming FDA decision on INO-3107 for recurrent respiratory papillomatosis by October 30, 2026.
INO presents high-risk speculation with potential for significant upside if FDA approval is secured, but carries substantial fundamental weaknesses including persistent cash burn and negative margins. Investors should weigh the binary outcome of the regulatory decision against the company's challenging financial position and technical bearishness.
VCIT trades at $78.27 with minimal daily movement (+0.04%). Technical indicators show a bearish trend with strong sell signals from moving averages, though oscillators are neutral. The ETF maintains consistent dividend distributions of $0.34 per share. Recent institutional interest includes Engineers Gate Manager LP's $1.27 million investment and HB Wealth Management's 242.9% position increase in Q3 2026.
VCIT offers a compelling 4.8% yield with low 0.03% expense ratio, positioning it favorably against competitors. However, the bearish technical outlook and interest rate sensitivity present near-term risks. The fund's intermediate-term corporate bond focus provides balanced risk-return profile for income-seeking investors amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
